Parkinson's Disease Drugs Market Globally Expected to Drive Growth till 2020

Parkinson’s disease is one of the most common degenerative movement disorder of the central nervous system that involve a progressive deterioration of dopamine generating cells in the region of midbrain known as substantia nigra. Loss of the dopamine causes impairment in the movements and sparks early motor symptoms such as rigidity, slowness of movements and tremors (shaking). Symptoms also include non-motor associated such as pain, swelling, constipation, sweating and depression. In most of the cases, symptoms start to appear at the age of around 50-55 years. However, in about 5-6% of cases the sufferers are below 40 years. Men have around 50-60% higher risk of getting Parkinson’s disease than female. The condition causes approximately 85,000 to 100,000 deaths each year and in 2013, according to a published article on global burden of diseases 103,000 deaths were recorded due to PD.

There are approximately 2 million people living with Parkinson’s in the United States and around 12 million people worldwide. Close to 70,000 Americans are diagnosed with Parkinson’s every year. United States expenditure on Parkinson’s each year is close to US$ 14.0 billion. In UK around 1.5 million people are suffering from Parkinson’s. Number of cases of Parkinson’s will increase about 30-35% by 2020 worldwide. Genetically Caucasians people have a higher prevalence than people of Asian and African descent. PD cases are more in the Midwest and Northeast regions of the US than Western and Southern regions.

As of now there is no single treatment available for PD as the disease symptoms differ from person to person based on their age, severity of disease and level of physical activity. Complete treatment regimen of PD includes medications, education, support, exercise, physical and speech therapy, and nutrition. The major aim of medication in PD is to increase the level of dopamine in the brain and to inhibit the action of other substances that affects dopamine such as acetylcholine.

Click For Full Report And Request TOC@ http://www.sa-brc.com/Global-Parkinsons-Disease-Drugs-Market-Assessment--Forecast-2016---2020/upcomingdetail32

Levodopa (L-dopa) is one of the most commonly used drug molecule for controlling the symptoms of Parkinson's disease, particularly rigidity and tremors. In recent years, drug manufacturers have tried to develop a formulation of carbidopa/levodopa that would release more slowly over time, and keep levodopa levels more even, thus reducing “off times” for people with Parkinson’s disease. In 2015, the U.S. FDA approved extended release carbidopa/levodopa combinations RYTARY by Impax Pharmaceuticals and Duopa by AbbVie. Duopa is a combination of carbidopa and levodopa and is the first to be effective for 16 hours, compared to oral formulations that last up to four hours following a single dose. Other popular carbidopa/levodopa combination for treatment currently in use is Sinemet. Emerging MAO-B inhibitor Safinamide (Newron Pharmaceuticals/Zambon Pharma) has won the EU approval in January 2015 and is also known to reduce dyskinesia or involuntary movements that are sometimes induced by Levodopa. Leading dopamine agonists, GSK’s/Skye Pharma’s Requip/XL/LKP/RP and Boehringer Ingelheim’s riapex/ Mirapexin/Sifrol also contribute significantly sales among therapies used to treat PD.

Some of the available PD drugs that will lose patent protection by 2020 are Teva/Lundbeck’s Azilect/Agilect, Novartis/Orion Pharma’s Comtan/Comtess/Staleva and GlaxoSmithKline’s Requip. Few of the leading pharmaceutical companies in the PD drugs market are GSK, Novartis, Newron Pharmaceuticals, Teva Pharma, Addex and Abbott. This report intends to provide qualitative analysis for market segmentation, treatment algorithms, drivers and inhibitors, opportunities (organic and non-organic), pipeline analysis and the competitive landscape of the market. Along with this quantitative analysis will be provided for treatment by disease segments and geography.

For More Research Reports@ http://www.sa-brc.com/Pharmaceuticals/upcoming2

About Us
Spearhead Acuity Business Research & Consulting Private Limited (SA-BRC) is a premium Life Science business intelligence and data analytics firm. SA-BRC team offers a wide range of business intelligence services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals, Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the entire value chain of healthcare industry. Our research and consulting capabilities extend across several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.

Contact Us
John Whitmore
10685-B Hazelhurst Drive,
Suite 17411
Houston, Texas 77043,
United States
Phone: +1(832)-426-3701
Email: sales@sa-brc.com
Website: www.sa-brc.com

This release was published on openPR.